[1] British Heart Foundation (2008) European Cardiovascular Disease Statistics. London.
[2] Ferdinand, K.C. (2011) Are Cardiovascular Benefits in Statin Lipid Affects Dependent on Baseline Lipid Levels? Current Atherosclerosis Reports, 13, 64-72.
http://dx.doi.org/10.1007/s11883-010-0149-9
[3] Steingo, L. (1993) Epidemiology of Hyperlipidemia and the Efficacy of Pravastatin Therapy. Current Therapeutic Research—Clinical and Experimental, 54, 290-299.
http://dx.doi.org/10.1016/S0011-393X(05)80629-0
[4] Yusuf, P.S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A. and Lanas, F. (2004) Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the INTERHEART Study): Case-Control Study. The Lancet, 364, 937-952.
http://dx.doi.org/10.1016/S0140-6736(04)17018-9
[5] Gotto Jr., A.M. and Moon, J.E. (2012) Management of Cardiovascular Risk: The Importance of Meeting Lipid Targets. American Journal of Cardiology, 110, 3A-14A.
http://dx.doi.org/10.1016/j.amjcard.2012.04.002
[6] Minder, C.M., Blaha, M.J., Horne, A., Michos, E.D., Kaul, S. and Blumenthal, R.S. (2012) Evidence-Based Use of Statins for Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 125, 440-446.
http://dx.doi.org/10.1016/j.amjmed.2011.11.013
[7] NICE (2010) Lipid Modifications: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. UK
[8] Alberton, M., Wu, P., Druyts, E., Briel, M. and Mills, E.J. (2012) Adverse Events Associated with Individual Statin Treatments for Cardiovascular Disease: An Indirect Comparison Meta-Analysis. QJM, 105, 145-157.
http://dx.doi.org/10.1093/qjmed/hcr158
[9] Mills, E.J., Wu, P., Chong, G., Ghement, I., Singh, S., Akl, E.A., Eyawo, O., Guyatt, G., Berwanger, O. and Briel, M.(2011) Efficacy and Safety of Statin Treatment for Cardiovascular Disease: A Network Meta-Analysis of 170,255 Patients from 76 Randomized Trials. QJM, 104, 109-124.
http://dx.doi.org/10.1093/qjmed/hcq165
[10] Stone, N.J., Robinson, J., Lichtenstein, A.H., Merz, C.N., Blum, C.B., Eckel, R.H., et al. (2013) ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 129, S1-S45.
[11] Mancini, G.B.J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R.A., Ng, D. and Pope, J. (2011) Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology, 27, 635-662.
http://dx.doi.org/10.1016/j.cjca.2011.05.007
[12] Law, M. and Rudnicka, A.R. (2006) Statin Safety: A Systematic Review. American Journal of Cardiology, 97, S52-S60.
http://dx.doi.org/10.1016/j.amjcard.2005.12.010
[13] JBS3 Board (2014) Joint British Societies’ Consensus Recommendations for the Prevention of Cardiovascular Disease (JBS3). Heart, 100, ii1-ii67.
[14] NICE (2014) Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. NICE, UK.
[15] Bays, H. (2005) Statin Safety: An Overview and Assessment of the Data. American Journal of Cardiology, 97, S6-S26.
http://dx.doi.org/10.1016/j.amjcard.2005.12.006
[16] Gaist, D., Rodríguez, L.A., Huerta, C., Hallas, J. and Sindrup, S.H. (2001) Lipid-Lowering Drugs and the Risk of Myopathy: A Population-Based Follow-Up Study. Epidemiology, 12, 565-569.
http://dx.doi.org/10.1097/00001648-200109000-00017
[17] Thompson, P.D., Clarkson, P.M. and Rosenson, R.S. (2006) An Assessment of Statin Safety by Muscle Experts. American Journal of Cardiology, 97, S69-S76.
http://dx.doi.org/10.1016/j.amjcard.2005.12.013
[18] Rosenson, R.S. (2004) Current Overview of Statin-Induced Myopathy. American Journal of Medicine, 116, 408-416.
http://dx.doi.org/10.1016/j.amjmed.2003.10.033
[19] Keogh, A., Macdonald, P., Kaan, A., Aboyoun, C., Spratt, P. and Mundy, J. (2000) Efficacy and Safety of Pravastatin versus Simvastatin after Cardiac Transplantation. Journal of Heart and Lung Transplantation, 19, 529-537.
http://dx.doi.org/10.1016/S1053-2498(00)00077-2
[20] Hippisley-Cox, J. (2010) Unintended Effects of Statins in Men and Women in England and Wales: Population Based Cohort Study Using the QResearch Database. BMJ, 340, c2197.
http://dx.doi.org/10.1136/bmj.c2197
[21] Carter, A.A., Gomes, T., Camacho, X., Juurlink, D.N., Shah, B.R. and Mamdani, M.M. (2013) Risk of Incident Diabetes among Patients Treated with Statins: Population Based Study. BMJ, 346, f2610.
http://dx.doi.org/10.1136/bmj.f2610
[22] Cholesterol Treatment Trialists’ (CTT) Collaboration (2010) Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170 000 Participants in 26 Randomised Trials. Lancet, 376, 1670-1681.
http://dx.doi.org/10.1016/S0140-6736(10)61350-5
[23] Kimberly, A.G., Monroe, A.K., Sharma, R., Ranasinghe, P.D., Chelladurai, Y. and Robinson, K.A. (2014) Effectiveness of Combination Therapy with Statin and Another Lipid-Modifying Agent Compared with Intensified Statin Monotherapy. Annals of Internal Medicine, 160, 468-476.
http://dx.doi.org/10.7326/M13-2526